At a glance
ClinicalIndex Comparison RecordN/ACompleted· 220 enrolled
Drug / intervention
Teriparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Myokines in Postmenopausal Osteoporosis
In Brief
An observational study evaluating Teriparatide and Denosumab for Osteoporosis, Postmenopausal. Completed, enrolled 220 participants across 1 site.
Detailed Summary
Circulating levels of several myokines will be measured in serum samples obtained from women in various categories of bone density and according to the presence of fracture or not as well as before and after treatment with teriparatide and denosumab
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Postmenopausal
CountriesGreece
CollaboratorsBeth Israel Deaconess Medical Center
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedDec 2019
Primary CompletionSep 2020
Study CompletionNov 2020
TodayJul 2026
First PostedDec 20, 2019
Enrollment StartJun 1, 2019
Primary CompletionSep 30, 2020
Study CompletionNov 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.5 years ago
Interventions
Teriparatidedrug
1 subcutaneous injection daily for 12 months
Denosumabdrug
1 subcutaneous injection every 6 months for 12 months